These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 8248891)

  • 1. Soluble MHC class I antigens (sHLA) and anti-HLA antibodies in heart and kidney allograft recipients.
    Zavazava N; Böttcher H; Ruchholtz WM
    Tissue Antigens; 1993 Jul; 42(1):20-6. PubMed ID: 8248891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Donor-derived soluble HLA plasma levels can not be used to monitor graft rejection in heart transplant recipients.
    Koelman CA; Vaessen LM; Balk AH; Weimar W; Doxiadis II; Claas FH
    Transpl Immunol; 2000 Mar; 8(1):57-64. PubMed ID: 10834611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of anti-HLA antibodies on the long-term survival of heart and kidney allografts.
    Barr ML; Cohen DJ; Benvenisty AI; Hardy M; Reemtsma K; Rose EA; Marboe CC; D'Agati V; Suciu-Foca N; Reed E
    Transplant Proc; 1993 Feb; 25(1 Pt 1):262-4. PubMed ID: 8438294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of HLA disparity, immunosuppressive regimen used, and type of kidney allograft on production of anti-HLA class-I antibodies after transplant and occurrence of rejection.
    Abdelnoor AM; Ajib R; Chakhtoura M; Daouk M; Medawar W; Uwaydah M; Sawah SI; Khauli RB
    Immunopharmacol Immunotoxicol; 2009; 31(1):83-7. PubMed ID: 18752168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flow cytometric detection of HLA-specific antibodies as a predictor of heart allograft rejection.
    Tambur AR; Bray RA; Takemoto SK; Mancini M; Costanzo MR; Kobashigawa JA; D'Amico CL; Kanter KR; Berg A; Vega JD; Smith AL; Roggero AL; Ortegel JW; Wilmoth-Hosey L; Cecka JM; Gebel HM
    Transplantation; 2000 Oct; 70(7):1055-9. PubMed ID: 11045642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of PRA-STAT, sHLA-EIA, and anti-human globulin-panel reactive antibody to identify alloreactivity in pretransplantation sera of heart transplant recipients: correlation to rejection and posttransplantation coronary artery disease.
    Kerman RH; Susskind B; Kerman D; Lam M; Gerolami K; Williams J; Kalish R; Campbell M; Katz S; Van Buren CT; Frazier H; Radovancevic B; Fife S; Kahan B
    J Heart Lung Transplant; 1998 Aug; 17(8):789-94. PubMed ID: 9730428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serologic allogeneic chimerism.
    McDonald JC; Adamashvili I; Zibari GB; Aultman DF; Mancini MC; McMillan RW; Gelder FB
    Transplantation; 1997 Sep; 64(6):865-71. PubMed ID: 9326412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble donor HLA class I and beta 2m-free heavy chain in serum of lung transplant recipients: steady-state levels and increases in patients with recurrent CMV infection, acute rejection episodes, and poor outcome.
    DeVito-Haynes LD; Jankowska-Gan E; Meyer KC; Cornwell RD; Zeevi A; Griffith B; Dauber J; Iacono A; Burlingham WJ; Love RB
    Hum Immunol; 2000 Dec; 61(12):1370-82. PubMed ID: 11163095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring of kidney and simultaneous pancreas-kidney transplantation rejection by release of donor-specific, soluble HLA class I.
    DeVito-Haynes LD; Jankowska-Gan E; Sollinger HW; Knechtle SJ; Burlingham WJ
    Hum Immunol; 1994 Jul; 40(3):191-201. PubMed ID: 7960963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Donor-specific antibodies against HLA, MICA, and GSTT1 in patients with allograft rejection and C4d deposition in renal biopsies.
    Alvarez-Márquez A; Aguilera I; Gentil MA; Caro JL; Bernal G; Fernández Alonso J; Acevedo MJ; Cabello V; Wichmann I; Gonzalez-Escribano MF; Núñez-Roldán A
    Transplantation; 2009 Jan; 87(1):94-9. PubMed ID: 19136897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of HLA-G expression in serum and biopsy samples of kidney transplant recipients.
    Poláková K; Bandžuchová H; Žilinská Z; Chreňová S; Kuba D; Russ G
    Immunobiology; 2015 Apr; 220(4):533-7. PubMed ID: 25468563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific sHLA in healthy donors and donor-specific sHLA in renal transplant patients.
    Borelli SD; Ferreira E; Oliveira AM; Krishnaswamy S; Hiraki DD; Grumet FC
    Hum Immunol; 1999 May; 60(5):430-4. PubMed ID: 10447402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble HLA-G expression and renal graft acceptance.
    Qiu J; Terasaki PI; Miller J; Mizutani K; Cai J; Carosella ED
    Am J Transplant; 2006 Sep; 6(9):2152-6. PubMed ID: 16780545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble HLA and anti-idiotypic antibodies in transplantation: modulation of anti-HLA antibodies by soluble HLA antigens from the graft and anti-idiotypic antibodies in renal and cardiac allograft recipients.
    Suciu-Foca N; Ho E; King DW; Yu YP; Yu-Kai S; Reed E; Cohen D; Brensilver JM; McCabe R; Rose E
    Transplant Proc; 1991 Feb; 23(1 Pt 1):295-6. PubMed ID: 1990536
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical relevance of pre and post-transplant immune markers in kidney allograft recipients: anti-HLA and MICA antibodies and serum levels of sCD30 and sMICA.
    Solgi G; Furst D; Mytilineos J; Pourmand G; Amirzargar AA
    Transpl Immunol; 2012 Mar; 26(2-3):81-7. PubMed ID: 22182633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post transplant development of MICA and anti-HLA antibodies is associated with acute rejection episodes and renal allograft loss.
    Panigrahi A; Gupta N; Siddiqui JA; Margoob A; Bhowmik D; Guleria S; Mehra NK
    Hum Immunol; 2007 May; 68(5):362-7. PubMed ID: 17462503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble total human leukocyte antigen class I and human leukocyte antigen-G molecules in kidney and kidney/pancreas transplantation.
    Rebmann V; Bartsch D; Wunsch A; Möllenbeck P; Golda T; Viebahn R; Grosse-Wilde H
    Hum Immunol; 2009 Dec; 70(12):995-9. PubMed ID: 19651178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HLA class I and class II antibodies: monitoring before and after kidney transplantation and their clinical relevance.
    Schönemann C; Groth J; Leverenz S; May G
    Transplantation; 1998 Jun; 65(11):1519-23. PubMed ID: 9645818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical and immunological evaluation of donor-specific soluble HLA in the circulation of liver transplant recipients.
    Mathew JM; Shenoy S; Phelan D; Lowell J; Howard T; Mohanakumar T
    Transplantation; 1996 Jul; 62(2):217-23. PubMed ID: 8755819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allosensitization to HLA and MICA is an important measure of renal graft outcome.
    Panigrahi A; Siddiqui JA; Rai A; Margoob A; Khaira A; Bhowmik D; Tiwari SC; Guleria S; Mehra NK
    Clin Transpl; 2007; ():211-7. PubMed ID: 18637472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.